Impact of combined lipid lowering with blood pressure control on coronary plaque regression: rationale and design of MILLION study

[1]  A. Sato,et al.  Impacts of age on coronary atherosclerosis and vascular response to statin therapy , 2014, Heart and Vessels.

[2]  S. Kihara,et al.  Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -- 2012. , 2013, Journal of atherosclerosis and thrombosis.

[3]  S. Kihara,et al.  Other types of primary hyperlipoproteinemia(hyperlipidemia). Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version. , 2013, Journal of atherosclerosis and thrombosis.

[4]  H. Daida,et al.  Intensively lowering both low-density lipoprotein cholesterol and blood pressure does not reduce cardiovascular risk in Japanese coronary artery disease patients. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[5]  T. Hiro,et al.  Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J). , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[6]  T. Ogihara,et al.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) , 2009, Hypertension Research.

[7]  Takafumi Hiro,et al.  Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[8]  Katsumi Miyauchi,et al.  Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin , 2009, Journal of the American College of Cardiology.

[9]  T. Ogihara,et al.  Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients , 2009, Hypertension Research.

[10]  Yun-dai Chen,et al.  Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia , 2008, Heart and Vessels.

[11]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[12]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[13]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[14]  P. Libby,et al.  Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure The CAMELOT Study: A Randomized Controlled Trial , 2004 .

[15]  K. Shimada,et al.  Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study , 2004, Circulation.

[16]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[17]  K. Nakajima,et al.  Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[18]  H. Thomas,et al.  The multiple risk factor intervention trial (MRFIT) II. The development of the protocol. , 1981, Preventive medicine.

[19]  W. Kannel,et al.  A general cardiovascular risk profile: the Framingham Study. , 1976, The American journal of cardiology.

[20]  S. Kihara,et al.  The elderly. , 2014, Journal of atherosclerosis and thrombosis.

[21]  W. Elliott.  Prevention of Cardiovascular Events With an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required Versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Tri , 2006 .

[22]  Eric J Topol,et al.  Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. , 2004, JAMA.